Veradermics (MANE) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Rhythm Pharmaceuticals is the larger company by market cap ($6.18 billion vs $5.28 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MANE | RYTM |
|---|---|---|
| Share price | $126.40 | $89.73 |
| Market cap | $5.28B | $6.18B |
| 1-day change | +13.93% | +1.45% |
| YTD return | — | -17.37% |
| 1-year return | — | -11.40% |
| 5-year return | — | +682.05% |
| EPS (TTM) | $-4.24 | $-3.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $189.76M |
| Revenue growth (YoY) | — | +45.83% |
| Net income (latest FY) | $-70.00M | $-196.54M |
| Gross margin | — | 89.73% |
| Operating margin | — | -101.19% |
| Net margin | — | -103.57% |
| 52-week high | $136.72 | $122.20 |
| 52-week low | $32.00 | $74.50 |
| Distance from 52-week high | -7.54% | -26.57% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +29.35% | +54.45% |
| Average volume | 729.81K | 649.06K |
| Shares outstanding | 41.78M | 68.85M |
| Employees | 37 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
MANE vs RYTM FAQ
Which is bigger, Veradermics or Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) is larger, with a market capitalization of $6.18B compared with $5.28B for Veradermics (MANE).
Are Veradermics and Rhythm Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.